Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

ICTT: Oral Anticancer Drug Rubitecan Shows Response Rate/Disease Stabilization in Some Patients With Advanced Stomach Cancer DUBLIN, CA -- November 12, 2001 -- SuperGen Inc. announced today that data from an ongoing phase II study of its oral anticancer compound rubitecan shows that the drug "is active and well-tolerated in patients previously treated for advanced gastric adenocarcinoma (stomach cancer), with minimal toxicity," said Alexandria T. Phan, M.D., of the department of gastrointestinal oncology at M. D. Anderson Cancer Center (University of Texas). Dr. Phan presented her clinical data to colleagues attending last week's "19th Annual Symposium on Innovative Cancer Therapy for Tomorrow (ICTT)" in New York City, which was being co-sponsored by Mount Sinai School of Medicine and The Chemotherapy Foundation. According to Dr. Phan, other recent studies of rubitecan have demonstrated activity and tolerance in patients with many different refractory (resistant to chemotherapy) solid tumors. However, Dr. Phan's ongoing phase II clinical trial of rubitecan is focused on patients with gastric cancer having either locally advanced unresectable (inoperable) or metastatic disease. These patients have been previously treated with no more than one regimen of chemotherapy. "These results are very promising," said Dr. Phan. "Future studies of rubitecan in combination with other active agents is certainly warranted." Most people in the United States do not receive a diagnosis until stomach cancer is advanced, when the five-year survival rate is only three percent, according to the Mayo Clinic. Gastric cancer is initially asymptomatic; the tumor may metastasize to the local lymph nodes, and may spread intraperitoneally (within the peritoneum, a membrane that lines the walls of the abdominal cavity) or hematogenously (by the bloodstream). Even with apparent localized disease, the five-year survival rate of patients with proximal gastric cancer is only 10-15 percent, according to the National Cancer Institute (NCI). Doctors diagnose about 22,000 cases of stomach cancer in the U.S. annually, and nearly 13,000 Americans with stomach cancer die annually. SOURCE: SuperGen Inc. E-mail this page to a friend or colleague! To print, use this version